Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two-Drug combo targets tough Non-Hodgkin's lymphoma

NCT ID NCT07819188

Disease control Sponsor: Sinocelltech Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing two experimental drugs, SCTB35 and SCTB41, in adults with B-cell non-Hodgkin's lymphoma that has returned or stopped responding to at least two prior treatments. Participants receive the drugs together, with or without chemotherapy, to find a safe dose and see whether tumors shrink. The trial has two parts: a first phase that looks for the highest dose people can tolerate, and a second phase that measures how many participants respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SCTB35 and SCTB41, two experimental antibody-based drugs given alone or with chemotherapy
What this could lead to
If the combination works, it could offer a new treatment option for people whose non-Hodgkin's lymphoma has come back or stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with about 90 participants, so researchers mainly want to find a safe dose and see early signs of benefit. The drugs may cause side effects, may not shrink tumors, or may help only a subset of patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 80 years (inclusive) at the time of informed consent * Histologically or cytologically confirmed B cell neoplasm. * Phase 1: Relapsed or refractory disease after at least two prior systemic therapy. * Measurable or evaluable disease at enrollment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Adequate organ and bone marrow function * Life expectancy of ≥ 3 months Exclusion Criteria: * Prior treatment with bispecific antibodies targeting both CD20 and CD3 * Prior treatment with antibodies targeting both PD-1/PD-L1, PD-(L)1/VEGF(R) or PD-(L)1/TGF-β * Eligible for high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT) * Known central nervous system (CNS) involvement by lymphoma * Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks * Chemotherapy and other non-investigational antineoplastic agents within 4 weeks or 5 half-lives (whichever is shorter) prior to first SCTB35 administration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell non Hodgkin lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NHL - non-Hodgkin's lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjing, Tianjing, 301636, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.